In recent years, targeted therapy with CDK4/6 inhibitors combined with endocrine therapy has made significant progress in the treatment of early and advanced HR + breast cancer, making it an important treatment option for HR + breast cancer. The gene discussed is CDK4; the disease is breast carcinoma.